Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondarily Infected Traumatic Skin Lesions
Conditions
Secondarily Infected Traumatic Skin Lesions
Trial Timeline
Feb 1, 2013 → May 6, 2019
NCT ID
NCT01876550About Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product is a phase 1 stage product being developed by Sun Pharmaceutical for Secondarily Infected Traumatic Skin Lesions. The current trial status is completed. This product is registered under clinical trial identifier NCT01876550. Target conditions include Secondarily Infected Traumatic Skin Lesions.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01876550 | Phase 1 | Completed |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85